StÃ©phane de Botton

List of Publications by Year
in descending order

43 papers	5,322 citations	257101 24 h-index	301761 39 g-index
45 all docs	45 docs citations	45 times ranked	4704 citing authors

#	Article	IF	Citations
1	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood, 2023, 141, 156-167.	0.6	27
2	Ivosidenib and Azacitidine inIDH1-Mutated Acute Myeloid Leukemia. New England Journal of Medicine, 2022, 386, 1519-1531.	13.9	186
3	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nature Medicine, 2022, 28, 1224-1231.	15.2	38
4	Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 57-65.	0.8	118
5	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood, 2021, 137, 524-532.	0.6	33
6	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. Blood, 2021, 137, 2827-2837.	0.6	36
7	Differentiation syndrome with lowerâ€intensity treatments for acute myeloid leukemia. American Journal of Hematology, 2021, 96, 735-746.	2.0	12
8	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer Medicine, 2021, 10, 6336-6343.	1.3	6
9	SOHO State of the Art Updates and Next Questions: IDH Inhibition. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 567-572.	0.2	0
10	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 421-428.	0.4	3
11	Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e986-e989.	0.2	3
12	Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 429-438.	0.4	2
13	IDH Inhibition. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S3-S4.	0.2	0
14	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Advances, 2020, 4, 1894-1905.	2.5	129
15	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Advances, 2020, 4, 1942-1949.	2.5	49
16	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood, 2020, 136, 698-714.	0.6	28
17	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood, 2020, 135, 463-471.	0.6	266
18	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. Blood, 2019, 134, 2414-2416.	0.6	14

#	Article	IF	Citations
19	Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. HemaSphere, 2019, 3, e203.	1.2	13
20	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood, 2019, 133, 676-687.	0.6	262
21	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. Blood, 2019, 134, 231-231.	0.6	23
22	Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. Blood, 2019, 134, 3722-3722.	0.6	1
23	Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. Blood, 2019, 134, 643-643.	0.6	37
24	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia, 2018, 32, 2008-2081.	3.3	18
25	Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Medicinal Chemistry Letters, 2018, 9, 300-305.	1.3	292
26	Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2. JAMA Oncology, 2018, 4, 1106.	3.4	157
27	Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. Leukemia and Lymphoma, 2018, 59, 1659-1665.	0.6	15
28	Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML. New England Journal of Medicine, 2018, 378, 2386-2398.	13.9	1,092
29	Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature Medicine, 2018, 24, 1167-1177.	15.2	157
30	Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. Leukemia Research, 2017, 54, 12-16.	0.4	2
31	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. Journal of Clinical Oncology, 2017, 35, 1223-1230.	0.8	37
32	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. Cancer Discovery, 2017, 7, 478-493.	7.7	350
33	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood, 2017, 130, 722-731.	0.6	1,173
34	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood, 2017, 130, 732-741.	0.6	300
35	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2017, 35, 185-193.	0.8	227
36	Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 343-343.	0.6	44

#	Article	IF	Citations
37	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. European Journal of Cancer, 2015, 51, 2386-2395.	1.3	32
38	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. Blood, 2015, 126, 2872-2872.	0.6	1
39	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. Blood, 2015, 126, 323-323.	0.6	57
40	Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA). Blood, 2015, 126, 2893-2893.	0.6	0
41	An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. Journal of Experimental Medicine, 2009, 206, 1701-1707.	4.2	75
42	A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.. Blood, 2009, 114, 632-632.	0.6	6
43	CXCR4 Blockade as a New Targeted Therapy for Acute Myeloide Leukemia Characterised by High Cell Surface Density of CXCR4.. Blood, 2009, 114, 4570-4570.	0.6	0